Navigation Links
China Sky One Medical, Inc.'s AMI Diagnostic Kit Recognized as a National Innovation Project by NDRC
Date:1/12/2010

eceive a subsidy from the Chinese government of RMB 6.00 million (approximately US $0.88 million) in 2010. In addition, National Innovation Projects receive a preferential income tax rate of 15%, versus the regular tax rate of 25%. Currently, three of China Sky One Medical's wholly-owned subsidiaries, Harbin TDR Medical Science and Technology, Heilongjiang Tianlong Pharmaceutical, and Harbin First Bioengineering, receive a preferential income tax rate of 15% because they have been granted the High-Technology Enterprise Certificate by the provincial government in Heilongjiang Province, which became effective January 1, 2009.

The AMI Diagnostic Kit, which entered the market in China in 2007, is used for early diagnosis of Myocardial Infarction (MI), also known as heart disease. The testing kit requires users to place a blood sample on a marker, and a positive (+) or negative (-) sign will result, showing whether the user should consult his or her doctor for further testing. More often than not, heart disease is likely to strike people who are overweight, smoke, or suffer from diabetes. Statistics show that over 60 million patients in China currently suffer from heart disease, with approximately eight million new cases each year. Recent medical studies have shown that heart failure and heart attacks are increasing among the younger adults in China, the result of several factors, including the fast pace of a more modern life style and increased pressure from work and school. Using the AMI Diagnostic Kit for early detection of heart disease can help to reduce these statistics. For the first nine months of 2009, the AMI Diagnostic Kit accounted for approximately 7.5% of the Company's total revenues.

About China Sky On
'/>"/>

SOURCE China Sky One Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmaron Expands Portfolio of Services with Acquisition of Bridge Laboratories China
2. China Medicine Announces Changes to Management Team
3. Sinovac Named One of Chinas Top 10 Most Competitive Companies Listed Overseas in 2009
4. Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group
5. Sinovacs CEO Weidong Yin Nominated for China Central Televisions Prestigious Economic Man-of-the-Year Award
6. China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
7. China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010
8. BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in Chinas National Insurance Catalog
9. China Biologic Products Approved to List on NASDAQ
10. China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits
11. Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 Reportlinker.com announces ... available in its catalogue:   ... for Optical Coherence Tomography (OCT) ... STUDY OBJECTIVES   ... to offer synopsis of the current and ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D ... results from the global Phase 3 PROMISE study ... simeprevir (TMC435) led to sustained virologic response 12 ... 79 percent of treatment-experienced genotype 1 chronic hepatitis ... all stages of liver fibrosis, when administered once ...
(Date:5/21/2013)... , May 21, 2013 U.S. spending on ... complex diseases such as cancer, multiple sclerosis and rheumatoid ... the end of 2015, according to a forecast released ... (Logo: http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) "As we ... and health plans to act so they can continue ...
Breaking Medicine Technology:Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5
... May 4 Roche Public Affairs Director Stacy Quinn ... Star by the Healthcare Businesswomen,s Association (HBA) at the organization,s annual awards luncheon ... , , ... for detail and has earned the appreciation and respect of the management team, ...
... In conjunction with DURECT Corporation,s (Nasdaq: DRRX ) first quarter 2010 ... will be broadcast live over the internet on Monday, May 10, 2010 ... , , ... , , ...
Cached Medicine Technology:Roche's Quinn Honored as 2010 HBA Rising Star 2Roche's Quinn Honored as 2010 HBA Rising Star 3DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call 2
(Date:5/21/2013)... Daily Gossip Magazine published well-documented articles that are meant to ... on the latest weight loss methods by publishing weekly in-depth ... review of Kyle Leon’s Customized Fat Loss Plan ... lose weight or stay in shape with the minimum effort. ... by a popular fitness trainer, Kyle Leon, who has made ...
(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker Waichman ... of victims injured by defective medical devices, is offering remarks ... case of the Estate of Fred E. Taylor v. Intuitive ... Orchard). A May 21, 2013, Bloomberg report noted ... acted like a “car dealership” in how it deployed its ...
(Date:5/21/2013)... 2013 Parker Waichman LLP, a national ... injured by defective medical devices, is addressing new research ... on May 15, 2013. The study found that magnetic ... that occur in patients with metal-on-metal hip implants even ... ) , “We’ve known for quite ...
(Date:5/21/2013)... One-year results from SOURCE XT one of the ... reported today at EuroPCR 2013 show good clinical ... device success for all access approaches, valve sizes and ... up 2688 consecutively enrolled patients (mean age 81.5 years) ... 93 centres in 17 countries between July 2010 and ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 The federal ... hip replacement lawsuits in U.S. District Court, ... response to a request from Plaintiffs’ Counsel to conduct ... The May 17th Order grants that request, and ... conducted. (In re: Wright Medical Technology, Inc., Conserve Hip ...
Breaking Medicine News(10 mins):Health News:Customized Fat Loss Plan Review and Diet Secrets Revealed By Daily Gossip Magazine 2Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 2Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 3Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3
... Based on finding of a recent study researchers say ... day is an effective preventive // measure for people ... anti-epileptic drug. Studies have also shown its success in ... neuralgia, and migraine headache. Since gabapentin often reduces migraines ...
... study reports that kids with asthma are more likely to ... moving or family relationships. // ,60 children who had ... had a history of chronic stress. Over 18 months, kids ... flow tests, which measured their breathing strength. Both kids and ...
... do much to relieve knee pain associated with osteoarthritis, ... studies comparing the drugs to placebos. ,The ... and around 3,000 received placebos. The average age of ... been experiencing symptoms for about eight years. Since long-term ...
... fatigue but can also be dangerous. In some cases ... hours can cause deep-vein thrombosis, a potentially serious condition ... pelvic veins. , ,The risk is greatest for ... cardiovascular disease, cancer and blood-clotting disorders, according to the ...
... could lead to an enlarged heart by early adulthood, ... .// ,Researchers followed 467 children for almost ... participants at childhood with data obtained at young adulthood. ... size. Participants who had the highest BMI levels in ...
... who take high doses of steroids are more than twice ... not, say researchers based on findings of a recent study. ... the skin, lungs, joints, digestive tract, such as asthma, inflammatory ... health records of 68,781 people who used steroids between 1993 ...
Cached Medicine News:
Sensitive Eyes drops keep soft contact lenses moist....
Lens Plus Sterile Saline Solution...
... Renu Multiplus No Rub formula is the ... today. All steps in one bottle without ... stores soft contact lenses and removes protein ... multi-purpose solution that contains Hydranate, a special ...
Sensitive Eyes sterile saline spray is the preservative-free aerosol saline solution for people with eyes sensitive to preservatives. Used for rinsing soft contact lenses after cleaning or thermal or...
Medicine Products: